Thomas Smith
Stock Analyst at Leerink Partners
(1.05)
# 3,539
Out of 4,827 analysts
71
Total ratings
29.03%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $0.37 | +170.27% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.54 | +486.32% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $1.28 | +446.88% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.35 | +566.67% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $10.56 | +269.32% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $3.29 | +690.27% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $0.81 | +1,130.92% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $6.75 | +196.30% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $615.11 | -29.28% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $42.70 | -15.69% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $0.79 | +782.72% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $13.85 | +51.62% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $12.02 | +274.53% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $6.60 | -9.09% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $4.79 | +25.39% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.07 | +369.48% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $39.36 | -56.81% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $18.40 | +247.83% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.84 | +292.38% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $7.75 | +274.19% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.87 | +805.92% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $0.33 | +3,550.75% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $27.01 | -55.57% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $4.62 | +116.45% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $2.98 | +13,322.82% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $13.80 | +479.71% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.37
Upside: +170.27%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.54
Upside: +486.32%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.28
Upside: +446.88%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.35
Upside: +566.67%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $10.56
Upside: +269.32%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $3.29
Upside: +690.27%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $0.81
Upside: +1,130.92%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $6.75
Upside: +196.30%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $615.11
Upside: -29.28%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $42.70
Upside: -15.69%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $0.79
Upside: +782.72%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $13.85
Upside: +51.62%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $12.02
Upside: +274.53%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $6.60
Upside: -9.09%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.79
Upside: +25.39%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.07
Upside: +369.48%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $39.36
Upside: -56.81%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $18.40
Upside: +247.83%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.84
Upside: +292.38%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $7.75
Upside: +274.19%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.87
Upside: +805.92%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.33
Upside: +3,550.75%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $27.01
Upside: -55.57%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $4.62
Upside: +116.45%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $2.98
Upside: +13,322.82%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $13.80
Upside: +479.71%